Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease crawled time : 13:30 save search
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
Published: 2024-03-04 (Crawled : 13:30) - globenewswire.com
PPRUF | News | $364.27 850
|
Consumer Non-Durables
|
| O: -0.59%
H: 0.27%
C: -1.83%
PPRUY | News | $36.96 220K
|
Manufacturing
|
| O: -1.85%
H: 0.2%
C: -0.07%
PCVX | $61.8 0.33% 51K
|
Health Technology
|
| O: 0.2%
H: 0.18%
C: -0.42%
STRO | $3.92 3.98% 180K
|
Health Technology
|
| O: 0.2%
H: 1.81%
C: -3.43%
vax-24 disease pneumococcal study
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
Published: 2024-03-04 (Crawled : 13:30) - globenewswire.com
FBIO | $1.8 2.86% 34K
|
Health Technology
|
| O: 2.47%
H: 5.02%
C: -8.03%
disease biotech million grant therapeutics therapy
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
Published: 2024-02-21 (Crawled : 13:30) - globenewswire.com
DYAI A | $1.53 2.4K
|
Health Technology
|
| O: 9.63%
H: 8.78%
C: 2.03%
institute disease israel research solutions collaboration
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
Published: 2024-02-15 (Crawled : 13:30) - globenewswire.com
PALI | $6.06 22.92% 20M
|
Manufacturing
|
| O: -3.01%
H: 2.99%
C: 1.45%
disease week
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
Published: 2024-01-29 (Crawled : 13:30) - globenewswire.com
PPRUF | News | $364.27 850
|
Consumer Non-Durables
|
| O: 0.92%
H: 0.76%
C: -1.38%
PPRUY | News | $36.96 220K
|
Manufacturing
|
| O: -0.55%
H: 1.4%
C: 1.28%
PCVX | $61.8 0.33% 51K
|
Health Technology
|
| O: 0.26%
H: 6.59%
C: 6.23%
STRO | $3.92 3.98% 180K
|
Health Technology
|
| O: -0.43%
H: 6.84%
C: 6.62%
vax-31 disease pneumococcal study
AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease
Published: 2024-01-23 (Crawled : 13:30) - biospace.com/
ANGO | $6.165 -1.52% 77K
|
Health Technology
|
| O: 1.66%
H: 0.33%
C: -2.28%
fda disease treat clearance
Delaware Selects Conduent to Implement Advanced Platform for Infectious Disease Tracking
Published: 2023-12-13 (Crawled : 13:30) - globenewswire.com
CNDT 4 | $3.095 1.48% 41K
|
Commercial Services
|
| O: -0.31%
H: 5.59%
C: 4.66%
disease advanced platform
Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
Published: 2023-11-16 (Crawled : 13:30) - globenewswire.com
BMEA | $11.27 4.06% 200K
|
Professional, Scientific, and T...
|
| O: -0.11%
H: 6.94%
C: 0.32%
bmf-219 disease six congress world one diabetes cardiovascular insulin
CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism
Published: 2023-11-14 (Crawled : 13:30) - globenewswire.com
CNTG | $0.4701 14K
|
Commercial Services
|
| O: 10.25%
H: 0.78%
C: -0.78%
disease global
BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 13:30) - globenewswire.com
BIVI | $0.4841 0.19% 150K
|
Health Technology
|
| O: -4.57%
H: 1.5%
C: 0.0%
biv201 meeting liver disease association positive trial study
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
Published: 2023-11-09 (Crawled : 13:30) - globenewswire.com
PPRUF | News | $364.27 850
|
Consumer Non-Durables
|
| O: -1.41%
H: 1.77%
C: -1.32%
PPRUY | News | $36.96 220K
|
Manufacturing
|
| O: 1.28%
H: 0.21%
C: -1.4%
PCVX | $61.8 0.33% 51K
|
Health Technology
|
| O: 0.59%
H: 0.63%
C: -5.62%
STRO | $3.92 3.98% 180K
|
Health Technology
|
| O: 4.12%
H: 0.0%
C: -11.07%
vax-31 disease pneumococcal study
Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases
Published: 2023-11-06 (Crawled : 13:30) - prnewswire.com
MBRX | $4.45 3.49% 2.4K
|
Health Technology
|
| O: 0.67%
H: 16.45%
C: 14.21%
lung disease positive treatment trial
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease
Published: 2023-10-27 (Crawled : 13:30) - globenewswire.com
ABOS | $3.27 4.47% 97K
|
Professional, Scientific, and T...
|
| O: -0.62%
H: 0.0%
C: 0.0%
acu193 disease alzheimer’s pharmaceuticals trials
MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial
Published: 2023-10-24 (Crawled : 13:30) - biospace.com/
MAIA | $2.29 1.33% 150K
|
|
| O: 19.49%
H: 4.72%
C: -12.88%
thio-101 lung disease control positive cancer cell ongoing trial
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2023-10-19 (Crawled : 13:30) - biospace.com/
RGLS | $2.25 2.27% 47K
|
Health Technology
|
| O: 6.38%
H: 0.0%
C: -8.18%
rgls8429 disease kidney treatment trial therapeutics
AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023
Published: 2023-10-10 (Crawled : 13:30) - biospace.com/
ABBV | News | $169.965 1.24% 890K
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
disease abbvie research week
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.
Published: 2023-10-10 (Crawled : 13:30) - biospace.com/
BHC | $8.535 1.01% 480K
|
Health Technology
|
| O: 1.18%
H: 1.81%
C: 0.52%
liver disease report health pharmaceuticals trends
Coya Therapeutics (Coya) Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)
Published: 2023-10-09 (Crawled : 13:30) - biospace.com/
COYA | News | $7.99 4.5K
|
|
| O: -0.25%
H: 4.71%
C: 3.23%
disease alzheimer’s therapeutics study
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2023-09-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.35 -0.08% 230K
|
Health Technology
|
| O: 0.63%
H: 0.5%
C: 0.31%
entyvio fda disease active therapy
Adaptive Announces Launch of Epic Integration for clonoSEQ®The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancers
Published: 2023-09-13 (Crawled : 13:30) - biospace.com/
ADPT | $2.655 5.78% 420K
|
Commercial Services
|
| O: 0.3%
H: 2.54%
C: -1.94%
clonoseq disease integration blood
Gainers vs Losers
| 89% | 11% |
Top 10 Gainers
MTTR | News M | $4.65 167.24% 9.8M
|
AGBA | $2.355 88.4% 34M
|
Finance
EDBL | News | $6.75 79.52% 1.5M
|
CZOO | $8.77 75.75% 11M
|
VNRX | $0.84 40.0% 2.6M
|
Health Technology
OPRT | News | $3.01 33.78% 6.8M
|
Finance
MLEC | $1.81 29.29% 2M
|
n/a
CMAX | $4.12 28.35% 65K
|
Manufacturing
MTC | $2.0 28.21% 1.7M
|
Technology Services
PEGY | $0.0586 27.95% 130M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.